Shots:
The agreement expands its previous contract for research which the companies signed in 2021 to include a new target organ
The new agreement will combine Pantherna’s mRNA platform with Astellas’ drug discovery capabilities to promote the research of regenerative medicine programs for new target organs by using a direct reprogramming approach and will promote the development of next-generation treatments using a new modality/technology based on the focus area approach strategy
Astellas will lead the drug discovery ideas, preparing candidate compounds for technology evaluation, and perform research to develop therapeutic modality while Pantherna will lead the technical information and development support
Ref: PRNewsswire | Image: Astellas
